Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and survival. Care for incident fractures in this...
Guardado en:
Autor principal: | John Sunyecz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/70bc2989b0ba406f9d28e9a36ede7d2b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Oliver Bock, et al.
Publicado: (2008) -
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis
por: Silvia Migliaccio, et al.
Publicado: (2007) -
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Philip Sambrook
Publicado: (2007) -
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: María J Moro-Álvarez, et al.
Publicado: (2008) -
Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
por: Esteban Jódar-Gimeno
Publicado: (2007)